Abstract
Introduction Population-based studies about the consequences of SARS-CoV-2 infection (COVID-19) in pregnancy are few and have limited generalizability to the Nordic population and health care systems.
Material and method This study examines pregnant women with COVID-19 in the five Nordic countries. Pregnant women were included if they were admitted to hospital between March 1 and June 30, 2020 and had a positive SARS-CoV-2 PCR test 14 days or fewer prior to the admission. Cause of admission was classified as obstetric or COVID-19 related.
Results In the study areas, 214 pregnant women with a positive test were admitted to hospital, of which 56 women needed hospital care due to COVID-19. The rate of admission due to COVID-19 was 0.4 per 1000 deliveries in Denmark, Finland, and Norway and 3.8 per 1000 deliveries in the Swedish regions. Women hospitalized because of COVID-19 were more frequently obese (P < 0.001) and had migrant background (P < 0.001) compared to the total population of women who delivered in 2018. Twelve women (21.4%) needed intensive care. Preterm delivery (n=12, 25%, P < 0.001) and cesarean delivery (n=21, 43,8%, P < 0.001) were more frequent in women with COVID-19 compared to the women who delivered in 2018. No maternal deaths, stillbirths or neonatal deaths were reported.
Conclusions The risk of admission due to severe COVID-19 disease in pregnancy was low in the Nordic countries. A fifth of the women required intensive care and we observed higher rates of preterm and cesarean deliveries. National public health policies appear to have had an impact on the rates of admission due to severe COVID-19 disease in pregnancy. Nordic collaboration is important in collecting robust data and assessing rare outcomes.
Key Message Risk of hospital admission due to COVID-19 infection among pregnant women was low in the Nordic countries, but varied between the countries, which is most likely related to different national public health strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The clinical trial management software EasyTrial, used for data management in Denmark, was provided for free for this study as the company offered free access to the software to COVID-19 research projects. The Nordic Federation of Societies of Obstetrics and Gynecology (NFOG) granted financial support to the planning, data collection and communication of results from this project. The funding sources had no influence on the study design, analysis, interpretation of data, or decision to submit the paper.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Danish study(DK) was approved by the Danish Patient Safety Authority (reg. no. 31-1521-252) and the regional Data Protection Agency in Region Zealand (reg. no. REG-022-2020). The Finnish study(FI) was approved by the review board at Helsinki University Hospital.(reg.no HUS1624/2020). In Iceland (IS), the study and data collection were approved by Landspitali University Hospital, the National Bioethics Committee (reg.no.VSNb2020050016/03.0I) and the Icelandic Data Protection Authority (reg.no.20-106). In Norway (NO), the data collection was approved by the data protection officer at the Norwegian Institute of Public health (NIPH) (reg. no. 20_11054) and the study was approved by the Western Regional Ethics Committee (reg. no.125890) The Swedish study was approved by the Swedish Ethical Review Authority (reg. no. 2020-03012) for Sahlgranska University Hospital (SaUH) and Skaane University Hospital (SKH) and reg.no. 2020-01499 for Karolinska University Hospital (KUH). The ethical approvals in DK, IS, NO and KUH exempted the studies from the principle of individual consent. In FI ethical approval is not required in register-based studies, this is included in the University Hospital review board approval. In SaUH and SkUH, women received written information about the study including an opt-out possibility.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
* Shared first authorship
Conflicts of interest None of the authors have stated any conflict of interest and all authors have completed the IJME form.
Funding information The clinical trial management software EasyTrial, used for data management in Denmark, was provided for free for this study as the company offered free access to the software to COVID-19 research projects.
The Nordic Federation of Societies of Obstetrics and Gynecology (NFOG) granted financial support to the planning, data collection and communication of results from this project.
The funding sources had no influence on the study design, analysis, interpretation of data, or decision to submit the paper.
Data Availability
Additional data will not be available.
Abbreviations
- BMI
- Body Mass Index
- COVID-19
- SARS-CoV-2 disease with symptoms
- CD
- Cesarean Delivery
- DK
- Denmark
- FI
- Finland
- GA
- Gestational age
- ICU
- Intensive Care Unit
- IS
- Iceland
- MBRN
- the Medical Birth Registry of Norway
- NICU
- Neonatal Intensive Care unit
- NIPH
- the Norwegian Institute of Public Health
- NO
- Norway
- SE
- Sweden
- UK
- United Kingdom
